studies

430A AASLD ABSTRACTS HEPATOLOGY, October, 2015
438
Sorafenib Therapy in HIV-infected Patients with Hepatocellular
Carcinoma (HCC)
Luciana Kikuchi 1 , Caitlin C. Citti 2,3 , Ting-Yi Chen 4 , Heather L.
Platt 3 , David E. Kaplan 5 , Meritxell Ventura-Cots 6 , Mamta K. Jain 4 ,
Eugenia Vispo 7 , Jorge Daruich 8 , Marina Nunez 9 , Pablo Barreiro 7 ,
Beatriz Minguez 6 , Ayse Aytaman 10 , David Rimland 11 , Norbert
Bräu 3,2 ; 1 Gastroenterology, Universidade de São Paulo, São
Paulo, Brazil; 2 Infectious Diseases and Liver Diseases, Icahn School
of Medicine at Mount Sinai, New York, NY; 3 James J. Peters VA
Medical Center, Bronx, NY; 4 University of Texas Southwestern
Medical Center, Dallas, TX; 5 University of Pennsylvania, Philadelphia,
PA; 6 Hospital Universitario Vall d’Hebron, Barcelona, Spain;
7 Hospital Carlos III, Madrid, Spain; 8 Universidad de Buenos Aires,
Buenos Aires, Argentina; 9 Wake Forest University, Winston-Salem,
NC; 10 VA New York Harbor HCS, Brooklyn, NY; 11 Atlanta VA
Medical Center, Atlanta, GA
BACKGROUND: Sorafenib is the only systemic chemotherapy
for HCC shown to decrease all-cause mortality. Little is known
about its effect in HIV-infected patients with HCC. METHODS:
HIV-infected patients with HCC who received sorafenib (with or
without TACE) were retrospectively identified from 1992-2013
in 38 centers in 8 countries. They were compared to HIV-infected
patients from the same cohort who received no effective
HCC therapy. RESULTS: Compared to 132 untreated patients,
the 22 patients receiving sorafenib were of similar age (51 vs.
53 years), but tended to have less frequently alcohol abuse
(18% vs. 38%, p=0.079), were diagnosed through HCC
screening more often (59 vs. 30%, p=0.009), and had lower
mean Child-Pugh scores (6.6 vs. 7.8, p=0.001). Sorafenib
patients had lower mean HIV viral loads (1.7 vs. 2.7 log10
copies/ml, p